MARKET WIRE NEWS

Sagimet Biosciences Inc. (NASDAQ : SGMT) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.


Quote


Last:$6.995
Change Percent: -2.71%
Open:$7.09
Close:$7.19
High:$7.21
Low:$6.95
Volume:178,619
Last Trade Date Time:06/24/2026 12:44:45 pm

Stock Data


Market Cap:$183,421,818
Float:25,724,585
Insiders Ownership:0.29%
Institutions:25
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.sagimet.com
Country:US
City:San Mateo

Recent News Releases


Subscribe to Our Newsletter

**MWN-AI FAQ is based on asking OpenAI questions about Sagimet Biosciences Inc. (NASDAQ: SGMT).

Link Market Wire News to Your X Account

Download The Market Wire News App